Zacks Investment Research
24 Nov 2025, 16:01 UTC · 45w ago
Verdict
Source says Buy. We score MD +0.90 across four claims.
Score confirms the headline.
Buy
Rating stated in the headline
+0.90strongly bullish
More positive than 96% of ticker scores this week
Search tags
What the story claims
4 claims · scored −1 bearish … +1 bullish
Pediatrix Medical Group's (MD) current year earnings consensus estimate increased 15.7% over the last 60 days.
So whatA nearly 16% upward revision in earnings consensus is a material fundamental improvement, though the mid-cap healthcare niche limits broad market impact.
More positive than 79% of claims this week
Grupo Cibest S.A. (CIB) saw its current year earnings consensus estimate increase 8.7% over the last 60 days.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
More positive than 65% of claims this week
Pediatrix Medical Group (MD) shares gained 35.4% over the last three months.
More positive than 65% of claims this week
La-Z-Boy Incorporated (LZB) witnessed its current year earnings consensus estimate increase 3.2% over the last 60 days.
More positive than 44% of claims this week
Which stocks this story touches
More positive than 96% of ticker scores this week
The company has a Zacks Rank #1, increasing earnings estimates, and strong price momentum.
More positive than 96% of ticker scores this week
The company has a Zacks Rank #1, increasing earnings estimates, and strong recent share gains.
More positive than 88% of ticker scores this week
The company has a Zacks Rank #1 and positive earnings estimate revisions.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
1h ago
Zacks Investment Research
2h ago
+13.0%
Price agrees with the score
$26.10 vs $23.10 close before publication (Nov 21) · not market-adjusted
MD chart →
